2023 - Research.com Medicine in Israel Leader Award
2022 - Research.com Medicine in Israel Leader Award
Raphael Mechoulam focuses on Cannabinoid, Cannabinoid receptor, Pharmacology, Endocannabinoid system and Cannabinoid receptor type 2. His Cannabinoid study incorporates themes from Agonist, Cannabinoid receptor antagonist and Ligand. His Cannabinoid receptor study is associated with Internal medicine.
His Pharmacology research is multidisciplinary, incorporating elements of Tetrahydrocannabinol, Cannabidiol, Dexanabinol and Traumatic brain injury. His Endocannabinoid system study combines topics from a wide range of disciplines, such as Signal transduction, Neuroscience, Immunology and 2-Arachidonoylglycerol. He combines subjects such as Cannabinoid Receptor Modulators, Progenitor cell, Endogenous agonist, Cannabinoid Receptor Agonists and Cannabinoid receptor type 1 with his study of Cannabinoid receptor type 2.
Raphael Mechoulam spends much of his time researching Pharmacology, Cannabinoid, Cannabinoid receptor, Cannabidiol and Endocannabinoid system. The Pharmacology study which covers Tetrahydrocannabinol that intersects with Organic chemistry. His biological study spans a wide range of topics, including Agonist, Endocrinology and Stereochemistry.
His studies in Anandamide, Cannabinoid receptor type 2 and Depolarization-induced suppression of inhibition are all subfields of Cannabinoid receptor research. His research links GPR18 with Cannabinoid receptor type 2. His research on Endocannabinoid system frequently links to adjacent areas such as Neuroscience.
His primary areas of study are Cannabidiol, Pharmacology, Cannabinoid, Endocannabinoid system and Cannabinoid receptor. The study incorporates disciplines such as Inflammation, Immunology and Anxiety in addition to Cannabidiol. His Pharmacology research includes themes of Receptor, Antagonist, Anxiolytic, Receptor antagonist and In vivo.
His Cannabinoid research focuses on subjects like Endocrinology, which are linked to Methylazoxymethanol acetate. The concepts of his Endocannabinoid system study are interwoven with issues in Neuroscience, Neuroprotection, Tetrahydrocannabinol, Endogeny and Traumatic brain injury. His study in Cannabinoid receptor type 2, Anandamide and Cannabinoid Receptor Agonists is carried out as part of his Cannabinoid receptor studies.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
ISOLATION AND STRUCTURE OF A BRAIN CONSTITUENT THAT BINDS TO THE CANNABINOID RECEPTOR
William A. Devane;Lumir Hanuš;Aviva Breuer;Roger G. Pertwee.
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.
Raphael Mechoulam;Shimon Ben-Shabat;Lumir Hanus;Moshe Ligumsky.
Biochemical Pharmacology (1995)
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
A C Howlett;F Barth;T I Bonner;G Cabral.
Pharmacological Reviews (2002)
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Y. Gaoni;R. Mechoulam.
Journal of the American Chemical Society (1964)
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2
Roger Guy Pertwee;A. C. Howlett;M. E. Abood;S. P. H. Alexander.
Pharmacological Reviews (2010)
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.
Tiziana Bisogno;Lumír Hanuš;Luciano De Petrocellis;Susanna Tchilibon.
British Journal of Pharmacology (2001)
2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor
Lumír Hanuš;Saleh Abu-Lafi;Ester Fride;Aviva Breuer.
Proceedings of the National Academy of Sciences of the United States of America (2001)
The Endocannabinoid System and the Brain
Raphael Mechoulam;Linda A. Parker.
Annual Review of Psychology (2013)
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury
David Panikashvili;Constantina Simeonidou;Shimon Ben-Shabat;Lumír Hanuš.
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb
Angelo A. Izzo;Francesca Borrelli;Raffaele Capasso;Vincenzo Di Marzo.
Trends in Pharmacological Sciences (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: